Compare PNRG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | SABS |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.5M | 344.8M |
| IPO Year | 1995 | 2020 |
| Metric | PNRG | SABS |
|---|---|---|
| Price | $211.50 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.64 |
| AVG Volume (30 Days) | 58.5K | ★ 585.9K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $126.40 | $2.10 |
| 52 Week High | $278.90 | $5.15 |
| Indicator | PNRG | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 26.55 |
| Support Level | $205.98 | N/A |
| Resistance Level | $225.59 | $3.99 |
| Average True Range (ATR) | 7.00 | 0.19 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 88.05 | 17.39 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.